BASEL (dpa-AFX) - Ligand Pharmaceuticals Inc (LGND) on Monday said the U.S.
Food and Drug Administration has approved an expanded use for Promacta
(eltrombopag), a product of Novartis (NVS), to include children 1 year of age
and older with chronic...
Novartis gains FDA approval for Promacta® providing new option for children,
ages 6 and older, with chronic ITP, a rare blood disorder
Novartis International AG /
Novartis gains FDA approval for Promacta® providing new option for children,...
Intertape Polymer Group, Inc. (OTCQB:ITPOF)
Q2 2014 Results Earnings Conference Call
August 06, 2014, 10:00 AM ET
Gregory A.C. Yull - CEO and President
Jeffrey Crystal - CFO
Sarah Hughes - Cormark...
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the initiation of a Phase 3 clinical program for its oral SYK inhibitor, fostamatinib, in patients with ITP (immune thrombocytopenic purpura). The focus of these clinical studies is to...
MONTREAL, QUEBEC and SARASOTA, FLORIDA -- (Marketwired) -- 07/07/14 -- Intertape Polymer Group Inc. (TSX: ITP) ("Intertape" or the "Company") is pleased to announce that its Board of Directors has amended the Company's dividend policy by...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Intertape Polymer Group (ITP):